"Pfizer Inc. and BioNTech today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses," the message reads.
It is noted that two doses of the vaccine may not be enough to protect against infection with the Omicron strain, and the third dose of Pfizer increases the amount of antibodies in the human body by 25 times.
It is stated that the third dose provides a similar level of neutralization of antibodies to Omicron, as observed after two doses against other strains of the virus that appeared before the new variant of the disease.
"However, … the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally."
As it was reported, British scientists have recently discovered a new B.1.1.529 Covid variant that has 32 mutations in the spike protein. This part of the virus is used by most vaccines to prime the immune system against Covid. The WHO Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) has named the coronavirus strain B.1.1.529 "Omicron". Omicron could replace the Delta strain and become the most dominant one across the world.
According to Komarovsky, the new strain has most likely reached Ukraine because it's been confirmed in the neighboring countries, namely Romania and Russia.
On December 8, scientists from Hong Kong showed the first image of Omicron.